4.6 Article

VSI: AOS THESIS 2019 Remission of Non-Infectious Anterior Scleritis: Incidence and Predictive Factors

Journal

AMERICAN JOURNAL OF OPHTHALMOLOGY
Volume 223, Issue -, Pages 377-395

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajo.2019.03.024

Keywords

-

Categories

Funding

  1. NATIONAL EYE INSTITUTE [EY014943]
  2. Research to Prevent Blindness
  3. Paul and Evanina Mackall Foundation
  4. RPB James S. Adams Special Scholar Award
  5. RPB Harrington Special Scholar Award
  6. National Eye Institute

Ask authors/readers for more resources

This study aimed to assess the remission rate and predictive factors of non-infectious anterior scleritis. Results showed that bilateral scleritis and comorbid systemic inflammatory diseases were associated with lower remission rates, while statin treatment within a certain period was linked to higher remission incidence. Confirmation studies on the efficacy of adjunctive statin therapy in enhancing scleritis remission are needed.
PURPOSE: To assess how often non-infectious anterior scleritis remits and identify predictive factors. METHODS: Our retrospective cohort study at four ocular inflammation subspecialty centers collected data for each affected eye/patient at every visit from center inception (1978, 1978, 1984, 2005) until 2010. Remission was defined as inactivity of disease off all suppressive medications at all visits spanning at least three consecutive months or at all visits up to the last visit (to avoid censoring patients stopping follow-up after remission). Factors potentially predictive of remission were assessed using Cox regression models. RESULTS: During 1,906 years' aggregate follow-up of 832 affected eyes, remission occurred in 214 (170 of 584 patients). Median time-to-remission of scleritis = 7.8 years (95% confidence interval [CI]: 5.7, 9.5). More remissions occurred earlier than later during follow-up. Factors predictive of less scleritis remission included scleritis bilaterality (adjusted hazard ratio [aHR] = 0.46, 95% CI: 0.32-0.65); and diagnosis with any systemic inflammatory disease (aHR = 0.36, 95% CI: 0.23-0.58), or specifically with Rheumatoid Arthritis (aHR = 0.22), or Granulomatosis with Polyangiitis (aHR = 0.08). Statin treatment (aHR = 1.53, 95% CI: 1.03-2.26) within <= 90 days was associated with more remission incidence. CONCLUSIONS: Our results suggest scleritis remission occurs more slowly in anterior scleritis than in newly diagnosed anterior uveitis or chronic anterior uveitis, suggesting that attempts at tapering suppressive medications is warranted after long intervals of suppression. Remission is less frequently achieved when systemic inflammatory diseases are present. Confirmatory studies of whether adjunctive statin treatment truly can enhance scleritis remission (as suggested here) are needed. (Am J Ophthalmol 2021;223:377-395. (c) 2019 Published by Elsevier Inc.)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available